In our previous studies [21-23], a full-length recombinant p53 was successfully delivered into human malignant glioma cells, oral and bladder cancer cells by fusing with poly-arginine, a cell-penetrating peptide (CPP). Here, TP53 is linked to urinary bladder cancer.